Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1093185

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1093185

Europe Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application (Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others), By Technology, By Country and Growth Forecast, 2022 - 2028

PUBLISHED:
PAGES: 91 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The Europe Antibody Drug Conjugates Market would witness market growth of 13.8% CAGR during the forecast period (2022-2028).

Antigens expressed predominantly on the surface of tumor cells are ideal targets for ADCs. Hematological malignancies express lineage-specific antigens, which have been intensively investigated as excellent candidates, with many particular ADCs already approved and others in research. However, lineage-specificity does not apply to solid tumors, because antigens are mostly "tumor-associated" rather than "tumor-specific," meaning they are expressed on tumor cells as well as normal cells. It means that all of these drugs have a portion of on-target/off-tumor toxicity that is reliant on normal cell expression of the specific target, as well as a lower quantity of intra-tumoral drug delivery.

Cancer is one of the most prevalent causes of mortality worldwide, accounting for 8.2 million deaths per year. Chemotherapy, radiation, immunotherapy, laser treatment, stem cell therapy, surgery, hyperthermia, photodynamic therapy, and other therapeutic approaches are used to treat cancer and tumors. In addition, chemotherapy was the primary therapeutic intervention for cancer treatment among these choices. This is based on the assumption that these drugs would not affect normal cells while killing quickly dividing tumor cells first. Nitrogen mustard was studied in people based on this premise, leading to the elimination of bone marrow and lymphoid tissues in cancer patients. DNA alkylation is how this chemotherapeutic drug causes cellular apoptosis.

The Europe region is witnessing the increasing incidence of cancer patients. As per 2015 data, the Department of Health and Social Care in the United Kingdom invests a substantial amount of money each year in cancer treatment and services. Biomarkers can be used to assess patients in a variety of clinical settings, such as estimating disease risk, screening for occult primary cancers, distinguishing benign from malignant findings or one type of malignancy from another, determining prognosis and prediction for cancer patients, and monitoring disease status, either to identify repeat or ascertain response or progression to therapy.

The unregulated development of abnormal cells in one or both lungs causes lung cancer. Regardless of the fact that lung cancer can infect persons who have never smoked, smokers are at the highest risk. Lung cancer risk rises with the length of time and amount of cigarettes smoked. At the work or in the environment, other risk factors comprise asbestos, some metals, secondhand smoke, some organic chemicals, and air pollution, radiation, and diesel emissions.

The Germany market dominated the Europe Antibody Drug Conjugates Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $920.6 Million by 2028. The UK market is anticipated to grow at a CAGR of 12.8% during (2022 - 2028). Additionally, The France market would showcase a CAGR of 14.6% during (2022 - 2028).

Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.

Scope of the Study

Market Segments covered in the Report:

By Application

  • Breast Cancer
  • Blood Cancer
  • Urothelial Cancer & Bladder Cancer
  • Others

By Technology

  • Cleavable Linker
  • Non-Cleavable Linker
  • Others

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Companies Profiled

  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Gilead Sciences, Inc.
  • Seagen, Inc.
  • ADC Therapeutics SA
  • Daiichi Sankyo Company, Limited

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Europe Antibody Drug Conjugates Market, by Application
    • 1.4.2 Europe Antibody Drug Conjugates Market, by Technology
    • 1.4.3 Europe Antibody Drug Conjugates Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Acquisition & mergers
    • 3.2.3 Approvals and Trials
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May - 2022, Mar) Leading Players

Chapter 4. Europe Antibody Drug Conjugates Market by Application

  • 4.1 Europe Breast Cancer Market by Country
  • 4.2 Europe Blood Cancer Market by Country
  • 4.3 Europe Urothelial Cancer & Bladder Cancer Market by Country
  • 4.4 Europe Others Market by Country

Chapter 5. Europe Antibody Drug Conjugates Market by Technology

  • 5.1 Europe Cleavable Linker Market by Country
  • 5.2 Europe Non-Cleavable Linker Market by Country
  • 5.3 Europe Others Market by Country

Chapter 6. Europe Antibody Drug Conjugates Market by Country

  • 6.1 Germany Antibody Drug Conjugates Market
    • 6.1.1 Germany Antibody Drug Conjugates Market by Application
    • 6.1.2 Germany Antibody Drug Conjugates Market by Technology
  • 6.2 UK Antibody Drug Conjugates Market
    • 6.2.1 UK Antibody Drug Conjugates Market by Application
    • 6.2.2 UK Antibody Drug Conjugates Market by Technology
  • 6.3 France Antibody Drug Conjugates Market
    • 6.3.1 France Antibody Drug Conjugates Market by Application
    • 6.3.2 France Antibody Drug Conjugates Market by Technology
  • 6.4 Russia Antibody Drug Conjugates Market
    • 6.4.1 Russia Antibody Drug Conjugates Market by Application
    • 6.4.2 Russia Antibody Drug Conjugates Market by Technology
  • 6.5 Spain Antibody Drug Conjugates Market
    • 6.5.1 Spain Antibody Drug Conjugates Market by Application
    • 6.5.2 Spain Antibody Drug Conjugates Market by Technology
  • 6.6 Italy Antibody Drug Conjugates Market
    • 6.6.1 Italy Antibody Drug Conjugates Market by Application
    • 6.6.2 Italy Antibody Drug Conjugates Market by Technology
  • 6.7 Rest of Europe Antibody Drug Conjugates Market
    • 6.7.1 Rest of Europe Antibody Drug Conjugates Market by Application
    • 6.7.2 Rest of Europe Antibody Drug Conjugates Market by Technology

Chapter 7. Company Profiles

  • 7.1 Takeda Pharmaceutical Company Limited
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Regional Analysis
    • 7.1.4 Research & Development Expense
    • 7.1.1 Recent strategies and developments:
      • 7.1.1.1 Partnerships, Collaborations, and Agreements:
      • 7.1.1.2 Acquisitions and Mergers:
  • 7.2 F. Hoffmann-La Roche Ltd.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental and Regional Analysis
    • 7.2.4 Research & Development Expense
    • 7.2.5 Recent strategies and developments:
      • 7.2.5.1 Partnerships, Collaborations, and Agreements:
  • 7.3 AstraZeneca PLC
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.5 Recent strategies and developments:
      • 7.3.5.1 Partnerships, Collaborations, and Agreements:
  • 7.4 GlaxoSmithKline PLC
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Partnerships, Collaborations, and Agreements:
      • 7.4.5.2 Approvals and Trials:
  • 7.5 Pfizer, Inc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Regional & Segmental Analysis
    • 7.5.4 Research & Development Expense
    • 7.5.5 Recent strategies and developments:
      • 7.5.5.1 Partnerships, Collaborations and Agreements:
  • 7.6 Astellas Pharma, Inc.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expense
    • 7.6.5 Recent strategies and developments:
      • 7.6.5.1 Partnerships, Collaborations, and Agreements:
      • 7.6.5.2 Approvals and Trials:
  • 7.7 Gilead Sciences, Inc.
    • 7.7.1 Company overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Research & Development Expenses
    • 7.7.4 Recent strategies and developments:
      • 7.7.4.1 Acquisitions and Mergers:
      • 7.7.4.2 Partnerships, Collaborations and Agreements:
  • 7.8 Seagen, Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Research & Development Expenses
    • 7.8.4 Recent strategies and developments:
      • 7.8.4.1 Partnerships, Collaborations, and Agreements:
  • 7.9 ADC Therapeutics SA
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Research & Development Expenses
    • 7.9.4 Recent strategies and developments:
      • 7.9.4.1 Partnerships, Collaborations, and Agreements:
      • 7.9.4.2 Approvals and Trials:
  • 7.10. Daiichi Sankyo Company, Limited
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Research & Development Expense
    • 7.10.4 Recent strategies and developments:
      • 7.10.4.1 Partnerships, Collaborations, and Agreements:

LIST OF TABLES

  • TABLE 1 Europe Antibody Drug Conjugates Market, 2018 - 2021, USD Million
  • TABLE 2 Europe Antibody Drug Conjugates Market, 2022 - 2028, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Antibody Drug Conjugates Market
  • TABLE 4 Acquisition & mergers - Antibody Drug Conjugates Market
  • TABLE 5 Approvals and trials- Antibody Drug Conjugates Market
  • TABLE 6 Europe Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
  • TABLE 7 Europe Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
  • TABLE 8 Europe Breast Cancer Market by Country, 2018 - 2021, USD Million
  • TABLE 9 Europe Breast Cancer Market by Country, 2022 - 2028, USD Million
  • TABLE 10 Europe Blood Cancer Market by Country, 2018 - 2021, USD Million
  • TABLE 11 Europe Blood Cancer Market by Country, 2022 - 2028, USD Million
  • TABLE 12 Europe Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
  • TABLE 13 Europe Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
  • TABLE 14 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 15 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 16 Europe Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
  • TABLE 17 Europe Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
  • TABLE 18 Europe Cleavable Linker Market by Country, 2018 - 2021, USD Million
  • TABLE 19 Europe Cleavable Linker Market by Country, 2022 - 2028, USD Million
  • TABLE 20 Europe Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
  • TABLE 21 Europe Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
  • TABLE 22 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 23 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 24 Europe Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
  • TABLE 25 Europe Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
  • TABLE 26 Germany Antibody Drug Conjugates Market, 2018 - 2021, USD Million
  • TABLE 27 Germany Antibody Drug Conjugates Market, 2022 - 2028, USD Million
  • TABLE 28 Germany Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
  • TABLE 29 Germany Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
  • TABLE 30 Germany Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
  • TABLE 31 Germany Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
  • TABLE 32 UK Antibody Drug Conjugates Market, 2018 - 2021, USD Million
  • TABLE 33 UK Antibody Drug Conjugates Market, 2022 - 2028, USD Million
  • TABLE 34 UK Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
  • TABLE 35 UK Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
  • TABLE 36 UK Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
  • TABLE 37 UK Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
  • TABLE 38 France Antibody Drug Conjugates Market, 2018 - 2021, USD Million
  • TABLE 39 France Antibody Drug Conjugates Market, 2022 - 2028, USD Million
  • TABLE 40 France Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
  • TABLE 41 France Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
  • TABLE 42 France Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
  • TABLE 43 France Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
  • TABLE 44 Russia Antibody Drug Conjugates Market, 2018 - 2021, USD Million
  • TABLE 45 Russia Antibody Drug Conjugates Market, 2022 - 2028, USD Million
  • TABLE 46 Russia Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
  • TABLE 47 Russia Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
  • TABLE 48 Russia Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
  • TABLE 49 Russia Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
  • TABLE 50 Spain Antibody Drug Conjugates Market, 2018 - 2021, USD Million
  • TABLE 51 Spain Antibody Drug Conjugates Market, 2022 - 2028, USD Million
  • TABLE 52 Spain Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
  • TABLE 53 Spain Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
  • TABLE 54 Spain Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
  • TABLE 55 Spain Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
  • TABLE 56 Italy Antibody Drug Conjugates Market, 2018 - 2021, USD Million
  • TABLE 57 Italy Antibody Drug Conjugates Market, 2022 - 2028, USD Million
  • TABLE 58 Italy Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
  • TABLE 59 Italy Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
  • TABLE 60 Italy Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
  • TABLE 61 Italy Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
  • TABLE 62 Rest of Europe Antibody Drug Conjugates Market, 2018 - 2021, USD Million
  • TABLE 63 Rest of Europe Antibody Drug Conjugates Market, 2022 - 2028, USD Million
  • TABLE 64 Rest of Europe Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
  • TABLE 65 Rest of Europe Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
  • TABLE 66 Rest of Europe Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
  • TABLE 67 Rest of Europe Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
  • TABLE 68 Key Information - Takeda Pharmaceutical Company Limited
  • TABLE 69 KEY INFORMATION - F. HOFFMANN-LA ROCHE LTD.
  • TABLE 70 KEY INFORMATION - ASTRAZENECA PLC
  • TABLE 71 Key Information - GlaxoSmithKline PLC
  • TABLE 72 Key Information - Pfizer, Inc.
  • TABLE 73 key information - Astellas Pharma, Inc.
  • TABLE 74 Key Information - Gilead Sciences, Inc.
  • TABLE 75 Key Information - Seagen Inc.
  • TABLE 76 Key Information - ADC Therapeutics SA
  • TABLE 77 Key Information - Daiichi Sankyo Company, Limited

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
  • FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May - 2022, Mar) Leading Players
  • FIG 5 Recent strategies and developments: Takeda Pharmaceutical Company Limited
  • FIG 6 Recent strategies and developments: Gilead Sciences, Inc.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!